Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma

被引:3
|
作者
Boh, Erin [1 ]
Kuraitis, Drew [1 ,2 ]
Jacobson, Abby [3 ]
Sikes, Martha [3 ]
机构
[1] Tulane Univ, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Dermatol, Buffalo, NY USA
[3] Ortho Dermatol, Div Bausch Hlth US LLC, Bridgewater, NJ USA
关键词
Cutaneous; T-cell; Lymphoma; Diagnosis; Inflammatory dermatoses; Non-Hodgkin lymphoma; Survey; MYCOSIS-FUNGOIDES; IMMUNOPATHOGENESIS; PROGRESSION; DUPILUMAB;
D O I
10.1007/s13555-023-00895-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionCutaneous T-cell lymphoma (CTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas characterized by various clinical, molecular, and histopathologic features of the skin. Variants of CTCL share many clinical features with common inflammatory skin diseases such as atopic dermatitis and psoriasis, making accurate and early diagnosis challenging in clinical settings. Inappropriate treatment or a delay in diagnosis can lead to increased morbidity and mortality. Here, we report findings from an online survey that investigated dermatology community practice, knowledge, and education surrounding CTCL.MethodsAn electronic survey of ten questions was developed and approved by physician experts in CTCL to assess experiences in diagnosing and treating CTCL among healthcare providers (HCPs). The survey was deployed to 10,600 US dermatology HCPs, including medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (NPs), and physician assistants (PAs) and excluding HCPs associated with CTCL centers of excellence.ResultsAmong 44 HCPs who responded and were eligible for inclusion, 82% had diagnosed between one and ten CTCL cases in the last 5 years. Most respondents (91%) reported that they include CTCL in their differential diagnoses after patients do not respond to treatment of more common conditions. Patients with CTCL were frequently diagnosed with other inflammatory dermatoses-most commonly dermatitis and psoriasis-before a CTCL diagnosis, and many were treated with ineffective therapies for years. The most common length of time before a CTCL diagnosis was made was between 1 and 3 years, though 16% of HCPs reported that patients were treated for other diseases or skin conditions for >= 5 years. Two-thirds of HCPs agreed that further education surrounding CTCL is needed.ConclusionsGiven the infrequency of CTCL and its similar presentation to other common dermatologic conditions, increased education of CTCL is needed in the dermatology community to improve patient outcomes.
引用
收藏
页码:835 / 842
页数:8
相关论文
共 50 条
  • [1] Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma
    Erin Boh
    Drew Kuraitis
    Abby Jacobson
    Martha Sikes
    Dermatology and Therapy, 2023, 13 : 835 - 842
  • [2] Cutaneous T-cell Lymphoma
    Weiner, David M.
    Rook, Alain H.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (05) : 1087 - 1110
  • [3] Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges
    Hague, Christina
    Farquharson, Nina
    Menasce, Lia
    Parry, Eileen
    Cowan, Richard
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2022, 83 (04)
  • [4] Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute
    Ruiz, Rosana
    Morante, Zaida
    Mantilla, Raul
    Mas, Luis
    Casanova, Luis
    Gomez, Henry L.
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2017, 92 (05) : 648 - 653
  • [5] Cutaneous T-cell lymphoma in a cardiac transplant recipient
    McMullan, DM
    Radovancevic, B
    Jackow, CM
    Frazier, OH
    Duvic, M
    TEXAS HEART INSTITUTE JOURNAL, 2001, 28 (03): : 203 - 207
  • [6] Cutaneous T-cell lymphoma: important diagnostic tools
    Edsall, L. C.
    Patterson, J. W.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2010, 145 (03): : 323 - 344
  • [7] How do we treat cutaneous T-cell lymphoma?
    Stranzenbach, Rene
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2021, 156 (05) : 534 - 544
  • [8] Romidepsin for cutaneous T-cell lymphoma
    Prince, H. Miles
    Dickinson, Michael
    Khot, Amit
    FUTURE ONCOLOGY, 2013, 9 (12) : 1819 - 1827
  • [9] Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma
    Trager, Megan H.
    Geskin, Larisa J.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2019, 154 (06): : 681 - 695
  • [10] Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T-Cell Lymphoma: A Retrospective Review From China
    Pang, Zhiyu
    Zhang, Shan
    Liu, Zhaorui
    Zhang, Wei
    Liu, Jie
    DERMATOLOGIC THERAPY, 2024, 2024